# Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter

Study · id `cardio:ct-nct01541865` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01541865](<https://clinicaltrials.gov/study/NCT01541865>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01541865

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

## Technical summary

Registry record NCT01541865. Allocation not applicable; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-11 (actual). Results posted on 2015-10-16.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 146 participants (enrolled count; ClinicalTrials.gov record NCT01541865, source copy `cardio:ctgov-nct01541865-2015-11-25`, retrieved 2026-10-26)
- Start date: 2012-02 (registry gives no type) (ClinicalTrials.gov record NCT01541865, source copy `cardio:ctgov-nct01541865-2015-11-25`, retrieved 2026-10-26)
- Primary completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01541865, source copy `cardio:ctgov-nct01541865-2015-11-25`, retrieved 2026-10-26)
- Completion: 2015-06 (actual) (ClinicalTrials.gov record NCT01541865, source copy `cardio:ctgov-nct01541865-2015-11-25`, retrieved 2026-10-26)
- Results first posted: 2015-10-16 (ClinicalTrials.gov record NCT01541865, source copy `cardio:ctgov-nct01541865-2015-11-25`, retrieved 2026-10-26)
- Countries: Australia; Austria; Belgium; France; Germany; Netherlands; New Zealand; Switzerland (ClinicalTrials.gov record NCT01541865, source copy `cardio:ctgov-nct01541865-2015-11-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01541865-2015-11-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
- Acronym: REDUCE-HTN
- Condition: Hypertension
- Intervention (Device): Renal Denervation
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Resistant hypertension (`cardio:resistant-hypertension`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 807b032b5c4e358944081b82c8f49cbdd765fc5cd28153587cb76d6e4ed81713
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
